Anti-SLAMF7 monoclonal antibody (specialist)
Elotuzumab
Brand names: Empliciti
Adult dose
Dose: 10mg/kg IV weekly cycles 1–2, then q2w (with lenalidomide-dexamethasone or pomalidomide-dexamethasone)
Route: IV
Frequency: Weekly then q2w
Clinical pearls
- NICE TA505: relapsed/refractory multiple myeloma after ≥1 prior therapy with lenalidomide-dexamethasone
- BSH myeloma guidelines
- Specialist haemato-oncology
Contraindications
- Hypersensitivity
- Active infection (relative)
Side effects
- Infusion reactions
- Fatigue
- Diarrhoea
- Pyrexia
- Cataracts
- Hepatotoxicity
- Second primary malignancies (in combination regimens)
- Infections
Interactions
- Live vaccines
- Other immunosuppressives
Monitoring
- FBC
- LFTs
- Infusion reactions
- Infections
- Eye review
Reference: BNF; NICE TA505; BSH myeloma guidelines; ESMO; SmPC; https://bnf.nice.org.uk/drugs/elotuzumab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158